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Case description
We present the case of a 72-year-old man with alcoholic cir-
rhosis Child–Pugh B (9 points) complicated by esophageal 
variceal bleeding in the past, hepatic encephalopathy (HE), 
and ascites. He was admitted to our department for HE. Lab-
oratory analysis showed pancytopenia, INR 1.4, normal liver 
function tests, serum creatinine 3.56 mg/dL, urea 171 mg/
dL, C-reactive protein of 8.39 mg/dL, bilirubin of 3.2 mg/
dL and albumin of 2.74 mg/dL. On urinalysis, a leukocyturia 
was found; and on urine culture, Escherichia coli was iso-
lated. Spontaneous bacterial peritonitis was excluded. Facing 
a decompensated liver cirrhosis Child–Pugh C (10 points) 
with hepatic encephalopathy in the context of urinary tract 
infection and acute kidney injury stage 3, he was started on 
ceftriaxone 2 g/day and albumin (60 g/day). After excluding 
other etiologies, hepatorenal syndrome type 1 was presumed. 
Despite initial improvement (creatinine 3.02 mg/dL) with 
the administration of albumin, 10 days later his creatinine 
reached a level of 4.9 mg/dL. Terlipressin was instituted in a 
dose of 1 mg every 6 h, which was optimized to 2 mg every 
6 h due to lack of improvement. The day after this dose esca-
lation, he developed skin necrosis on the tip of the first digit 
of the left foot (Fig. 1a), and cyanosis of all of the fingers of 
the right foot with initial signs of necrosis of the third, fourth 
and fifth digits (Fig. 1b). These changes were most likely due 
to terlipressin-induced skin necrosis; therefore, this medica-
tion was immediately stopped. Ischemic features improved 
in a few days with the complement of surgical debridement.
Image of the feet of the patient where it is visible necrosis 
of the skin on the tip of the first finger of the left foot (a) and 
cyanosis of all of the fingers of the right with initial signs 
of necrosis of the third, fourth and fifth fingers (b). This 
necrosis was attributed to terlipressin
Terlipressin is a synthetic analogue of the hormone 
vasopressin [1, 2]. It promotes vasoconstriction, and has 
a preferential action on the splanchnic circulation where 
it lowers portal venous pressure [1]. It has two main indi-
cations in patients with portal hypertension: treatment of 
bleeding esophageal varices and hepatorenal syndrome 
[1]. Terlipressin is the most studied pharmacological treat-
ment for type 1 hepatorenal syndrome, and is effective in 
40–50% of cases [3]. It is generally started at a dose of 
1 mg/4–6 h, and increased to a maximum of 2 mg/4–6 h 
if there is no reduction in serum creatinine of at least 25% 
compared to the baseline value at day 3 of therapy [3]. It 
is considered a safe drug, and the most common adverse 
event, although relatively rare (< 5%), is diarrhea [1]. 
Ischemic complications are very rare, with a prevalence 
of less than 2% [1], and there are only 22 reported cases 
of skin necrosis related to terlipressin administration [2]. 
The occurrence of skin necrosis has been explained due to 
the presence of the vasopressin receptor type 1 in the skin 
and adipocytes besides the splanchnic circulation, kidney 
and bladder [2]. For treatment, weaning of terlipressin is 
usually sufficient although sildenafil, a vasodilatator, has 
been used with success [4].
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